Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Raw Materials (2025)

Outlook Therapeutics (OTLK) has disclosed Raw Materials for 1 consecutive years, with $2.4 million as the latest value for Q4 2025.

  • Quarterly Raw Materials changed N/A to $2.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.4 million through Dec 2025, changed N/A year-over-year, with the annual reading at $2.4 million for FY2025, N/A changed from the prior year.
  • Raw Materials for Q4 2025 was $2.4 million at Outlook Therapeutics, roughly flat from $2.4 million in the prior quarter.
  • The five-year high for Raw Materials was $2.4 million in Q3 2025, with the low at $2.4 million in Q3 2025.